Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon

X
Trial Profile

A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colon cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2022 Results of association of VEGFR, VEGFA, and CD31, with clinical outcomes and treatment benefit in dMMR and pMMR, presented at the 2022 Gastrointestinal Cancers Symposium
    • 08 Jun 2021 Results (n=1509 )evaluating to quantify the different molecules of TIME including T cells, macrophages, and immune checkpoint proteins (ICPs), and determine their association with clinical outcomes and treatment benefit, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
    • 16 Jan 2020 Results (n=6501) of pooled analysis of six clinical trials (NCT00079274; NCT00096278; NCT00004931; NCT00275210; NCT00265811; NCT00112918) examining the change of outcomes over 10-year period in patients with stage 3 colon cancer who were treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database, published in the Annals of Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top